Department of Neurosurgery, Huaian First Hospital, Nanjing Medical University, Huaian City, 223300, People's Republic of China.
Med Oncol. 2012 Dec;29(5):3472-7. doi: 10.1007/s12032-012-0259-z. Epub 2012 May 27.
MicroRNA-335 (miR-335), as a transcript of genomic region chromosome 7q32.2, acts as a tumor suppressor or tumor promoter in various human malignancies. Especially, it has been reportedly shown to be an oncogene in human glioma cell line in vitro, but its expression in human glioma tissues is not yet determined. The aim of this study was to investigate the clinical significance of miR-335 expression in glioma. MiR-335 expression in human gliomas and nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay. The association of miR-335 expression with clinicopathological factors and prognosis of glioma patients was statistically analyzed. The expression level of miR-335 in glioma tissues was significantly higher than that in corresponding nonneoplastic brain tissues (P < 0.001). In addition, high miR-335 expression was significantly associated with a higher WHO grade (P = 0.001). Survival analysis demonstrated that patients with high miR-335 expression tumors had significantly shorter survival times than those with low miR-335 expression tumors (P = 0.01) and that miR-335 was an independent prognostic factor (P = 0.02). Especially, subgroup analyses according to tumor histologic grade revealed that the mean survival time of patients with high grade (III-IV) was significantly worse for high miR-335 expression group than for low miR-335 expression group (P = 0.002), but no significant difference was found for patients with WHO grade I-II (P = 0.16). These results indicated that miR-335 expression was increased in human gliomas and was associated with advanced tumor progression. Furthermore, miR-335 expression was demonstrated for the first time to be an independent marker for predicting the clinical outcome of patients with gliomas.
微小 RNA-335（miR-335）作为基因组区域 7q32.2 的转录物，在各种人类恶性肿瘤中充当肿瘤抑制因子或肿瘤促进因子。特别是，据报道，它在体外的人类神经胶质瘤细胞系中是一种癌基因，但它在人类神经胶质瘤组织中的表达尚未确定。本研究旨在探讨 miR-335 表达在神经胶质瘤中的临床意义。通过实时定量 RT-PCR 检测 miR-335 在人神经胶质瘤和非肿瘤性脑组织中的表达。统计分析 miR-335 表达与神经胶质瘤患者临床病理因素和预后的关系。神经胶质瘤组织中 miR-335 的表达水平明显高于相应的非肿瘤性脑组织（P<0.001）。此外，高 miR-335 表达与更高的 WHO 分级显著相关（P=0.001）。生存分析表明，miR-335 高表达肿瘤患者的生存时间明显短于 miR-335 低表达肿瘤患者（P=0.01），miR-335 是独立的预后因素（P=0.02）。特别是，根据肿瘤组织学分级的亚组分析表明，高 miR-335 表达组高级别（III-IV）患者的平均生存时间明显差于 miR-335 低表达组（P=0.002），但 WHO 分级 I-II 患者无显著差异（P=0.16）。这些结果表明，miR-335 在人神经胶质瘤中表达增加，与肿瘤进展有关。此外，miR-335 表达首次被证明是预测神经胶质瘤患者临床预后的独立标志物。
